Moderna reins in 2023 COVID vaccine forecast, shares tumble
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Moderna (MRNA) downside has played out, HSBC raises rating
November 3, 2023 9:49 AM EDTModerna (NASDAQ: MRNA) was raised to Hold from Reduce at HSBC on Friday, with the firm raising the price target for the stock to $89 from $69 per share.
The investment bank's analyst, Yifeng Liu, said that the downside they saw for the company has... More
